Recorded Webinar from June 9, 2020


Generic PK methods for the quantification of mAbs using Gyrolab® and LC–MS/MS


In this webinar, we will investigate ligand binding assays (LBAs) and LC–MS/MS generic PK methods for the quantification of therapeutic monoclonal antibodies in pre-clinical species. We will show a comparison of a generic LBA assay on Gyrolab® and a generic workflow by LC–MS/MS using signature-peptide quantification. We will show you the assay performance for each platform using pembrolizumab as a model drug and also show you the impact of anti-drug antibodies on the different assay platforms. We will conclude with a recommendation for when to choose which platform. 


What will you learn?

  • How generic PK workflows for LBAs on the Gyrolab platform and LC–MS/MS platforms can be used for biotherapeutic quantification 
  • What the impact of anti-drug antibodies is on microfluidic ligand-binding immunoassays and LC–MS/MS PK methods for biotherapeutic quantification 
  • How to choose the best platform (Gyrolab or LC–MS/MS) for different biotherapeutic quantification scenarios 


johannes santa
Johannes Stanta, PhD
Senior Scientific Manager
Covance Laboratories (NJ, USA)




If you have problems to view the webinar please contact


Please register to access the webinar